Lupin Receives Tentative Approval for Generic HIV Treatment Drug from USFDA

Lupin has received tentative approval from the US FDA for its generic version of the HIV treatment drug Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets. The approval is for the 50 mg/200 mg/25 mg strength, which will be manufactured at Lupin's Nagpur facility. The estimated annual sales of the drug in the US were $16,237 million in July 2025.

Lupin Limited, a prominent generic drugmaker, has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg. This approval marks a significant milestone for Lupin, as it paves the way for the production of a generic version of Gilead Sciences' Biktarvy® Tablets, 50 mg/200 mg/25 mg.

The tentative approval signifies that Lupin's product is bioequivalent to Biktarvy® and indicated for the treatment of human immunodeficiency virus (HIV) infection in adults and pediatric patients weighing at least 25 kg. The tablets will be manufactured at Lupin's Nagpur facility in India, ensuring a robust supply chain for the generic drug.

The estimated annual sales of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets (RLD Biktarvy) in the U.S. were $16,237 million as of July 2025, according to IQVIA Market Access and Technology (MAT) data Lupin receives USFDA tentative approval for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets^[2]. This figure underscores the market potential for Lupin's generic version of the drug.

The approval from the U.S. FDA is a strategic move for Lupin, positioning the company to capitalize on the growing demand for affordable HIV treatment options. It also highlights Lupin's commitment to innovation and its ability to develop high-quality generic drugs that meet international regulatory standards.

In conclusion, Lupin's tentative approval for its generic HIV treatment drug marks a significant step forward in the company's efforts to expand its product portfolio and increase its market presence. This development is likely to be closely watched by investors and financial professionals, given the substantial market potential and the company's track record in the generic drug industry.